Clinical trial
Genetic Predictors of Benefit to Pembrolizumab
NCT02710396
Study timeline
Study start (actual)2016-05-31Date precision: day
Registry last updated2023-07-24
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Carcinoma, Non-Small-Cell Lungunresolved
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
CarboplatinDRUG · verified · RxNorm: carboplatin
Nab-paclitaxelDRUG
PemetrexedDRUG · verified · RxNorm: pemetrexed
Sponsors & collaborators
Columbia Universitylead sponsor
Merck Sharp & Dohme LLCcollaborator
Massachusetts General Hospitalcollaborator
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02710396 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.